RSV NEWCO
RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus (RVS), one of the leading causes of virus-related death for infants, particularly premature infants. Elderly people are also at risk from RSV.
RSV NEWCO
Industry:
Health Care Health Diagnostics Medical Medical Device
Status:
Active
Total Funding:
50 K USD
Similar Organizations
Neurava
Neurava is working to develop a first of its kind, wearable diagnostic for epilepsy patients, including those at risk of SUDEP.
Quantitative Radiology Solutions
Quantitative Radiology Solutions offers advanced body-wide quantification of medical images.
RightAir
RightAir is developing noninvasive ventilators for COPD patients.
VigorSential
VigorSential is Testing and developing a low-dose vaccine to control a bacterium mainly affecting cattle.
Xip
Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - RSV NewCo
More informations about "RSV NewCo"
Summary: Statement on the prevention of respiratory syncytial …
Organization: Public Health Agency of Canada. Date published: 2024-07-12. Cat.: HP40-364/2-2024E-PDF ISBN: 978-0-660-71993-1 Pub.: 240205. On this page. ... NACI recommends that …See details»
WHO releases first-ever position paper on …
4 days ago Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect infants against respiratory …See details»
RSV NewCo - Drug pipelines, Patents, Clinical trials - Synapse
May 7, 2025 100 Translational Medicine associated with RSV NewCo. Login to view more data. Corporation Tree. Boost your research with our corporation tree data. login. or. view full …See details»
Georgia Research Alliance - GRA
RSV NewCo Industry: Treatment for Respiratory Syncytial Virus. RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus (RVS), one of the leading causes of …See details»
Respiratory syncytial virus (RSV) - World Health Organization (WHO)
Mar 25, 2025 RSV is specific and pathogenic for humans and infects cells along the human respiratory tract, from the nose to the lungs. RSV causes a wide spectrum of respiratory …See details»
Vaccination schedule for Respiratory syncytial virus (RSV)
World Health Organization Immunization Data portal presents global, regional, and country summaries of vaccine-preventable disease reported cases, vaccination coverage data, …See details»
Updated guidance on respiratory syncytial virus (RSV) vaccines for ...
Mar 13, 2025 As there was an insufficient number of hospitalizations during the study period to estimate VE, RSV-LTRD associated shortness of breath was used as a proxy for mRNA-1345 …See details»
WHO outlines recommendations to protect infants …
5 days ago Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect infants against respiratory …See details»
Respiratory syncytial virus (RSV) vaccines: Canadian Immunization …
To prevent severe RSV disease during their first and second RSV seasons, RSV monoclonal antibodies are recommended for infants and children with chronic lung disease . Nirsevimab is …See details»
RSV Vaccine Guidance for Older Adults | RSV | CDC - Centers for …
The RSV vaccine is not currently an annual vaccine, meaning eligible adults do not need to get a dose every RSV season. Currently, CDC recommends only a single dose of RSV vaccine for …See details»
RSV NewCo - Drug pipelines, Patents, Clinical trials - Synapse
Explore RSV NewCo with its drug pipeline, therapeutic area, technology platform, 4 news. Data. Feature. Plans. Sign Up for Free. Request Demo. Sign Up for Free. Last update 02 May 2024. …See details»
RSV NewCo - Funding, Financials, Valuation & Investors
RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus. New. Resources. Advanced Search ... Experience the new Crunchbase, powered by AI . Experience …See details»
Spinovit - Crunchbase
Organization. Spinovit . Connect to CRM . Save . Summary Financials People Signals & News Similar Companies. Similar Companies. Edit Similar Companies Section. Companies like …See details»
Merck’s anti-RSV antibody expands protection for infants
2 days ago A positive push for RSV vaccine rollouts in low- and middle-income countries came in September last year, when the World Health Organization’s Strategic Advisory Group of …See details»
WHO Endorses First-Ever RSV Vaccination Guidance to
3 days ago “RSV is an incredibly infectious virus that infects people of all ages, but is especially harmful to infants, particularly those born premature, when they are most vulnerable to severe …See details»
RSV NewCo - Crunchbase
RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus.See details»
RSV wasn’t as hard on U.S. babies last winter. This may be why
May 16, 2025 Last winter’s respiratory syncytial virus, or RSV, season wasn’t as brutal for U.S. babies. A new study suggests two preventive tools — a maternal vaccine and a monoclonal …See details»
WHO Approves Merck’s Anti-RSV Antibody and One-Time Shot to …
13 hours ago The World Health Organization (WHO) has approved and recommended two new immunization tools to protect infants from respiratory syncytial virus (RSV), which is the …See details»
WHO Issues Recommendations To Fight RSV In Babies- How …
22 hours ago Summary RSV leads to over 100,000 infant deaths annually, but WHO’s latest guidance recommends maternal vaccines and monoclonal antibodies like nirsevimab to …See details»
WHO outlines recommendations to protect infants against RSV ...
2 days ago The World Health Organization (WHO) published its first-ever position paper on immunisation products to protect infants against respiratory syncytial virus (RSV) – the leading …See details»